Medicine
Kimyrsa 1200 mg/40 mL powder for injection
Kimyrsa 1200 mg/40 mL powder for injection is a prescription medicine containing Oritavancin for intravenous use, marketed by Melinta Therapeutics, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Storage KIMYRSA is supplied as a sterile white to off-white or pink…
Key facts
- Active ingredient (INN)
- Oritavancin
- Brand
- Kimyrsa
- Strength
- 1200 mg/40 mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 1 vial
- Marketing authorisation holder
- Melinta Therapeutics
- Manufacturer
- Melinta Therapeutics
- Origin register
- US FDA, United States
- Storage
- Storage KIMYRSA is supplied as a sterile white to off-white or pink lyophilized powder in single-dose clear glass vials containing 1,200 mg of oritavancin.
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J01XA05 Oritavancin
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 23 March 2021
- Identifiers
- RxCUI 2532361, 2532366DailyMed set ID 5e755c40-6e73-4572-b474-4d8a131693d1NDC 70842-225Application NDA214155
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 1 vial in 1 carton / 40 mL in 1 vial | 70842-225-01 | Melinta Therapeutics | 23 March 2021 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Other strengths and forms of Oritavancin
Clinical summary
Oritavancin is a lipoglycopeptide antibacterial indicated for the treatment of adult patients with acute bacterial skin and skin structure infections caused or suspected to be caused by susceptible isolates of designated Gram-positive microorganisms, among other approved uses. MedsAcross supplies Oritavancin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about OritavancinFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- Orbactiv prescribing information (Melinta Therapeutics) · U.S. National Library of Medicine, DailyMed
- Tenkasi (previously Orbactiv): European public assessment report (EPAR) · European Medicines Agency
Need Kimyrsa 1200 mg/40 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.